LRRTM4

Summary

LRRTM4 (leucine rich repeat transmembrane neuronal 4, HGNC:19411) is a protein-coding gene on chromosome 2p12, encoding Leucine-rich repeat transmembrane neuronal protein 4 (Q86VH4). May play a role in the development and maintenance of the vertebrate nervous system.

Predicted to enable heparan sulfate proteoglycan binding activity. Predicted to be involved in regulation of synapse assembly. Predicted to act upstream of or within AMPA glutamate receptor clustering; positive regulation of synapse assembly; and regulation of presynaptic membrane organization. Predicted to be located in postsynaptic membrane. Predicted to be part of AMPA glutamate receptor complex. Predicted to be active in several cellular components, including GABA-ergic synapse; photoreceptor ribbon synapse; and postsynaptic density membrane.

Source: NCBI Gene 80059 — RefSeq curated summary.

At a glance

• GWAS associations: 28
• Clinical variants (ClinVar): 83 total
• MANE Select transcript: NM_001134745

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19411
Approved symbol	LRRTM4
Name	leucine rich repeat transmembrane neuronal 4
Location	2p12
Locus type	gene with protein product
Status	Approved
Aliases	FLJ12568
Ensembl gene	ENSG00000176204
Ensembl biotype	protein_coding
OMIM	610870
Entrez	80059

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 6 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000409088, ENST00000409093, ENST00000409282, ENST00000409884, ENST00000409911, ENST00000456154, ENST00000491242

RefSeq mRNA: 5 — MANE Select: NM_001134745 NM_001134745, NM_001282924, NM_001282928, NM_001330370, NM_024993

CCDS: CCDS46346, CCDS46347, CCDS74530, CCDS82475

Canonical transcript exons

ENST00000409884 — 4 exons

Exon	Start	End
ENSE00001585504	77521668	77521818
ENSE00001588312	76747685	76748916
ENSE00001588336	77522109	77522376
ENSE00001589606	77518318	77519864

Expression profiles

Bgee: expression breadth ubiquitous, 144 present calls, max score 97.42.

FANTOM5 (CAGE): breadth broad, TPM avg 3.4776 / max 401.9012, expressed in 295 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
29301	1.3577	166
29300	0.7558	156
29298	0.4692	142
29299	0.3989	121
29296	0.2985	104
29302	0.1442	69
29297	0.0270	9
29292	0.0204	7
29293	0.0040	2
29294	0.0019	1

Top tissues by expression

266 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	97.42	gold quality
oocyte	CL:0000023	90.12	gold quality
cortical plate	UBERON:0005343	88.90	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	83.58	gold quality
prefrontal cortex	UBERON:0000451	81.28	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	79.19	gold quality
ganglionic eminence	UBERON:0004023	78.31	gold quality
frontal cortex	UBERON:0001870	77.86	gold quality
neocortex	UBERON:0001950	77.54	gold quality
Brodmann (1909) area 9	UBERON:0013540	76.38	gold quality
ventricular zone	UBERON:0003053	76.24	gold quality
right frontal lobe	UBERON:0002810	75.71	gold quality
anterior cingulate cortex	UBERON:0009835	75.68	gold quality
primary visual cortex	UBERON:0002436	75.59	gold quality
cingulate cortex	UBERON:0003027	75.58	gold quality
middle temporal gyrus	UBERON:0002771	75.33	silver quality
cerebral cortex	UBERON:0000956	75.26	gold quality
Brodmann (1909) area 23	UBERON:0013554	74.77	gold quality
occipital lobe	UBERON:0002021	73.34	gold quality
superior frontal gyrus	UBERON:0002661	73.26	gold quality
telencephalon	UBERON:0001893	72.57	gold quality
buccal mucosa cell	CL:0002336	72.50	silver quality
postcentral gyrus	UBERON:0002581	71.47	gold quality
forebrain	UBERON:0001890	70.45	gold quality
parietal lobe	UBERON:0001872	70.41	silver quality
nucleus accumbens	UBERON:0001882	69.49	gold quality
orbitofrontal cortex	UBERON:0004167	69.31	silver quality
caudate nucleus	UBERON:0001873	68.88	gold quality
Brodmann (1909) area 46	UBERON:0006483	68.73	silver quality
temporal lobe	UBERON:0001871	68.43	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	7602.48
E-HCAD-25	yes	5311.07
E-GEOD-180759	yes	4129.24
E-ANND-3	yes	3.99
E-HCAD-30	no	6078.07

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

88 targeting LRRTM4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6077	99.99	68.04	2299
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-10527-5P	99.91	72.28	3754

Literature-anchored findings (GeneRIF, showing 2)

• Targeted sequencing of the LRRTM gene family in suicide attempters with bipolar disorder. (PMID:31854516)
• LRRTM4 Terminal Exon Duplicated in Family with Tourette Syndrome, Autism and ADHD. (PMID:35052406)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	LRRTM4	ENSDARG00000078839
danio_rerio	lrrtm4l1	ENSDARG00000080015
danio_rerio	lrrtm4l2	ENSDARG00000099386
danio_rerio	LRRTM4	ENSDARG00000106522
mus_musculus	Lrrtm4	ENSMUSG00000052581
rattus_norvegicus	Lrrtm4	ENSRNOG00000021938

Paralogs (22): DCN (ENSG00000011465), RTN4R (ENSG00000040608), ASPN (ENSG00000106819), FLRT3 (ENSG00000125848), FLRT1 (ENSG00000126500), LRRC4 (ENSG00000128594), LRRC4B (ENSG00000131409), PODNL1 (ENSG00000132000), LRTM1 (ENSG00000144771), LRRC4C (ENSG00000148948), LRRTM1 (ENSG00000162951), LRRC15 (ENSG00000172061), PODN (ENSG00000174348), BGN (ENSG00000182492), LRRC19 (ENSG00000184434), FLRT2 (ENSG00000185070), GP1BA (ENSG00000185245), RTN4RL1 (ENSG00000185924), RTN4RL2 (ENSG00000186907), NYX (ENSG00000188937), LRRC66 (ENSG00000188993), LRRTM3 (ENSG00000198739)

Protein

Protein identifiers

Leucine-rich repeat transmembrane neuronal protein 4 — Q86VH4 (reviewed: Q86VH4)

All UniProt accessions (4): B8ZZ84, C9JM64, Q86VH4, Q4KMX1

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in the development and maintenance of the vertebrate nervous system. Exhibits strong synaptogenic activity, restricted to excitatory presynaptic differentiation.

Subunit / interactions. Peripherally associated with AMPAR complex. AMPAR complex consists of an inner core made of 4 pore-forming GluA/GRIA proteins (GRIA1, GRIA2, GRIA3 and GRIA4) and 4 major auxiliary subunits arranged in a twofold symmetry. One of the two pairs of distinct binding sites is occupied either by CNIH2, CNIH3 or CACNG2, CACNG3. The other harbors CACNG2, CACNG3, CACNG4, CACNG8 or GSG1L. This inner core of AMPAR complex is complemented by outer core constituents binding directly to the GluA/GRIA proteins at sites distinct from the interaction sites of the inner core constituents. Outer core constituents include at least PRRT1, PRRT2, CKAMP44/SHISA9, FRRS1L and NRN1. The proteins of the inner and outer core serve as a platform for other, more peripherally associated AMPAR constituents, including LRRTM4. Alone or in combination, these auxiliary subunits control the gating and pharmacology of the AMPAR complex and profoundly impact their biogenesis and protein processing.

Subcellular location. Cell membrane. Postsynaptic cell membrane.

Tissue specificity. Expressed in neuronal tissues.

Similarity. Belongs to the LRRTM family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q86VH4-1	1	yes
Q86VH4-2	2

RefSeq proteins (5): NP_001128217, NP_001269853, NP_001269857, NP_001317299, NP_079269 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001611	Leu-rich_rpt	Repeat
IPR003591	Leu-rich_rpt_typical-subtyp	Repeat
IPR032675	LRR_dom_sf	Homologous_superfamily
IPR050333	SLRP	Family

Pfam: PF13855

UniProt features (22 total): repeat 10, glycosylation site 3, domain 2, topological domain 2, splice variant 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86VH4-F1	74.45	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 58, 126, 291

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6794361	Neurexins and neuroligins
R-HSA-112316	Neuronal System
R-HSA-6794362	Protein-protein interactions at synapses

MSigDB gene sets: 148 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, GOBP_SYNAPSE_ASSEMBLY, GOBP_POSITIVE_REGULATION_OF_SYNAPSE_ASSEMBLY, GOBP_REGULATION_OF_CELL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GGGTGGRR_PAX4_03, GOBP_POSITIVE_REGULATION_OF_NERVOUS_SYSTEM_DEVELOPMENT, ATGTTAA_MIR302C, SRF_Q5_01, IRF7_01, CEBP_Q2, NKX62_Q2, GOBP_POSITIVE_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, GOBP_CELL_JUNCTION_ORGANIZATION

GO Biological Process (1): positive regulation of synapse assembly (GO:0051965)

GO Molecular Function (2): signaling receptor activity (GO:0038023), protein binding (GO:0005515)

GO Cellular Component (4): plasma membrane (GO:0005886), postsynaptic membrane (GO:0045211), membrane (GO:0016020), synapse (GO:0045202)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Protein-protein interactions at synapses	1
Neuronal System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
synapse assembly	1
positive regulation of nervous system development	1
regulation of synapse assembly	1
positive regulation of cell junction assembly	1
molecular transducer activity	1
binding	1
membrane	1
cell periphery	1
synaptic membrane	1
postsynapse	1
cellular anatomical structure	1
cell junction	1

Protein interactions and networks

STRING

1630 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LRRTM4	GPC4	O75487	947
LRRTM4	CNPY2	Q9Y2B0	854
LRRTM4	PTPRS	Q13332	853
LRRTM4	CTNNA2	P26232	822
LRRTM4	GPC1	P35052	722
LRRTM4	TRAPPC10	P48553	636
LRRTM4	GPC3	P51654	583
LRRTM4	NRXN1	Q9ULB1	554
LRRTM4	NRXN2	Q9P2S2	529
LRRTM4	CPQ	Q9Y646	491
LRRTM4	CCDC167	Q9P0B6	489
LRRTM4	ARFGEF3	Q5TH69	479
LRRTM4	LLPH	Q9BRT6	460
LRRTM4	RFX8	Q6ZV50	457
LRRTM4	NLGN2	Q8NFZ4	449

IntAct

9 interactions, top by confidence:

A	B	Type	Score
LRRTM4	AP3B1	psi-mi:“MI:0914”(association)	0.530
LRRTM4	SGPL1	psi-mi:“MI:0914”(association)	0.530
LRRTM4	Dlg4	psi-mi:“MI:0407”(direct interaction)	0.440
SCRIB	CHD2	psi-mi:“MI:0914”(association)	0.350
ZNF426	ABLIM3	psi-mi:“MI:0914”(association)	0.350
PILRA	NID2	psi-mi:“MI:0914”(association)	0.350
LRRTM3	URB1	psi-mi:“MI:0914”(association)	0.350

BioGRID (32): LRRTM4 (Affinity Capture-MS), LRRTM4 (Affinity Capture-MS), LRRTM4 (Affinity Capture-MS), LRRTM4 (Affinity Capture-Western), LRRTM4 (Proximity Label-MS), LRRTM4 (Affinity Capture-RNA), LRRTM4 (Affinity Capture-RNA), CDK11B (Affinity Capture-MS), AFF4 (Affinity Capture-MS), CNPY4 (Affinity Capture-MS), CHRAC1 (Affinity Capture-MS), CXXC1 (Affinity Capture-MS), CENPB (Affinity Capture-MS), AP3B1 (Affinity Capture-MS), BLK (Affinity Capture-MS)

ESM2 similar proteins: A0N0X6, A4IIW9, B0BLW3, B1H134, B1H234, B4F7C5, D3ZAL8, D3ZTV3, D4A7P2, E5DHB5, F1NUK7, F7D3V9, O43155, O43300, O94898, P58681, Q32Q07, Q3SXY7, Q3URE9, Q504C1, Q50L44, Q52KR2, Q5R482, Q5R6T0, Q5RDJ4, Q61809, Q66HV9, Q6RKD8, Q6UXK5, Q70AK3, Q7L985, Q80XG9, Q80ZD7, Q80ZD8, Q80ZD9, Q86VH4, Q86VH5, Q8BGA3, Q8BGT1, Q8BLU0

Diamond homologs: A1A4H9, B4F7C5, D3ZAL8, D4A6D8, D4A7P2, O43300, O75093, P58874, Q5R6B1, Q80XG9, Q86UE6, Q86VH4, Q86VH5, Q8BGA3, Q8BZ81, Q8C2S7, Q8K377, Q920A0, Q9BGP6, Q9UBM4, O88279, P70186, Q1ENI8, Q3ZBN5, Q80TR4, Q99MQ4, Q9BXN1, O02678, Q80ZD7, Q80ZD8, A3KNN3, A6H789, A6H793, A6NJW4, A8WHP9, D4AC13, G5EFX6, O00468, O19045, O35367

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	75
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2883 predictions. Top by Δscore:

Variant	Effect	Δscore
2:76748923:A:C	acceptor_gain	1.0000
2:76748914:CAT:C	acceptor_gain	0.9900
2:76748915:ATCTG:A	acceptor_loss	0.9900
2:76748916:TC:T	acceptor_loss	0.9900
2:76748918:T:A	acceptor_loss	0.9900
2:76748923:A:AC	acceptor_gain	0.9900
2:77024359:ATTT:A	donor_gain	0.9900
2:77109390:C:A	donor_gain	0.9900
2:77121661:A:AT	donor_gain	0.9900
2:77227074:TGC:T	donor_gain	0.9900
2:76748912:GGCAT:G	acceptor_gain	0.9800
2:76748913:GCAT:G	acceptor_gain	0.9800
2:76748914:CATC:C	acceptor_gain	0.9800
2:76748915:AT:A	acceptor_gain	0.9800
2:76748917:C:CC	acceptor_gain	0.9800
2:76748921:A:AC	acceptor_gain	0.9800
2:76748921:A:C	acceptor_gain	0.9800
2:76923367:CAT:C	acceptor_gain	0.9800
2:77004734:A:AC	donor_gain	0.9800
2:77004735:C:CC	donor_gain	0.9800
2:77043975:ATT:A	donor_gain	0.9800
2:77121660:C:CT	donor_gain	0.9800
2:76822900:CCATA:C	acceptor_gain	0.9700
2:77011789:T:C	donor_gain	0.9700
2:77024341:T:TA	donor_gain	0.9700
2:77114556:T:C	acceptor_gain	0.9700
2:76791046:A:AC	donor_gain	0.9600
2:76791047:C:CC	donor_gain	0.9600
2:76984007:C:CT	donor_gain	0.9600
2:76984008:T:TT	donor_gain	0.9600

AlphaMissense

3891 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:77518568:A:G	L434P	1.000
2:77518574:A:G	L432P	1.000
2:77518574:A:T	L432H	1.000
2:77518577:G:T	A431D	1.000
2:77518582:A:C	S429R	1.000
2:77518582:A:T	S429R	1.000
2:77518584:T:G	S429R	1.000
2:77518586:C:T	G428E	1.000
2:77518587:C:G	G428R	1.000
2:77518587:C:T	G428R	1.000
2:77518852:A:C	C339W	1.000
2:77518853:C:G	C339S	1.000
2:77518853:C:T	C339Y	1.000
2:77518854:A:G	C339R	1.000
2:77518854:A:T	C339S	1.000
2:77518924:G:C	C315W	1.000
2:77518925:C:G	C315S	1.000
2:77518926:A:G	C315R	1.000
2:77518926:A:T	C315S	1.000
2:77518930:C:A	W313C	1.000
2:77518930:C:G	W313C	1.000
2:77518932:A:G	W313R	1.000
2:77518932:A:T	W313R	1.000
2:77518936:A:C	N311K	1.000
2:77518936:A:T	N311K	1.000
2:77519080:A:C	N263K	1.000
2:77519080:A:T	N263K	1.000
2:77519224:G:C	N215K	1.000
2:77519224:G:T	N215K	1.000
2:77519234:A:G	L212P	1.000

dbSNP variants (sampled 300 via entrez): RS1000000707 (2:77135057 A>G), RS1000002136 (2:77006138 C>T), RS1000002662 (2:77065054 GAAT>G), RS1000003156 (2:76781750 G>A,C), RS1000004667 (2:77051714 G>T), RS1000006784 (2:77039776 T>C), RS1000012402 (2:77249581 T>A,C), RS1000013847 (2:77498256 A>T), RS1000015034 (2:77139019 T>A), RS1000016376 (2:77277456 C>A,T), RS1000020914 (2:76776567 T>C), RS1000023142 (2:77287447 T>G), RS1000027975 (2:76762618 G>A,T), RS1000032144 (2:77460633 G>A,C), RS1000032469 (2:77208840 C>T)

Disease associations

OMIM: gene MIM:610870 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

28 associations (top):

Study	Trait	p-value
GCST002337_174	Amyotrophic lateral sclerosis (sporadic)	2.000000e-08
GCST002701_36	Verbal declarative memory	5.000000e-06
GCST002985_1	Middle childhood and early adolescence aggressive behavior	6.000000e-07
GCST002986_1	Childhood and early adolescence aggressive behavior	5.000000e-08
GCST003657_6	Attention deficit hyperactivity disorder symptom score	6.000000e-06
GCST003901_12	Cognitive decline (age-related)	3.000000e-06
GCST007006_2	Logical memory (delayed recall) in normal cognition	7.000000e-08
GCST007201_24	Schizophrenia	1.000000e-07
GCST007201_409	Schizophrenia	1.000000e-06
GCST007323_13	Risk-taking tendency (4-domain principal component model)	7.000000e-09
GCST007326_39	Number of sexual partners	7.000000e-10
GCST007565_186	Morning person	6.000000e-19
GCST007565_70	Morning person	5.000000e-24
GCST007576_269	Chronotype	2.000000e-10
GCST007576_315	Chronotype	5.000000e-24
GCST007576_369	Chronotype	5.000000e-11
GCST008144_1	Fasting plasma glucose	8.000000e-06
GCST008368_17	Plasma anti-thyroid peroxidase levels	5.000000e-06
GCST009464_33	Facial morphology	4.000000e-08
GCST010057_2	Lung function	1.000000e-06
GCST010135_23	Oily fish consumption	8.000000e-10
GCST010140_15	Pork consumption	8.000000e-10
GCST010292_1	Response to lamotrigine and valproic acid in genetic generalized epilepsy	8.000000e-07
GCST010396_61	Gut microbiota (bacterial taxa, hurdle binary method)	8.000000e-06
GCST010536_6	Carotid plaque maximum area	3.000000e-06
GCST010538_7	Sum of carotid plaque area	3.000000e-07
GCST010762_1	Hypotension and cognitive impairment	6.000000e-06
GCST010989_204	Body size at age 10	4.000000e-15

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004874	memory performance
EFO:0006805	word list delayed recall measurement
EFO:0007860	ADHD symptom measurement
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0004312	vital capacity
EFO:0008111	diet measurement
EFO:0007874	gut microbiome measurement
EFO:0006501	carotid plaque build
EFO:0009819	comparative body size at age 10, self-reported

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

20 total (human), top 20 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases expression	4
trichostatin A	affects cotreatment, decreases expression	2
Cadmium	decreases expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, increases methylation	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	decreases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arbutin	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	decreases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.